↓ Skip to main content

Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial

Overview of attention for article published in Trials, February 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
119 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial
Published in
Trials, February 2015
DOI 10.1186/s13063-014-0528-6
Pubmed ID
Authors

Alistair Nichol, Craig French, Lorraine Little, Jeffrey Presneill, D James Cooper, Samir Haddad, Jacques Duranteau, Olivier Huet, Markus Skrifvars, Yaseen Arabi, Rinaldo Bellomo

Abstract

Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis. The erythropoietin in traumatic brain injury trial is a stratified prospective, multi-centre, randomised, blinded, parallel-group, placebo-controlled phase III trial. It aims to determine whether the administration of erythropoietin compared to placebo improves neurological outcome in patients with moderate or severe traumatic brain injury at six months after injury. The trial is designed to recruit 606 patients between 15 and 65 years of age with severe (Glasgow Coma Score: 3 to 8) or moderate (Glasgow Coma Score: 9 to 12) traumatic brain injury in Australia, New Zealand, Kingdom of Saudi Arabia, France, Finland, Germany and Ireland. Trial patients will receive either subcutaneous erythropoietin or placebo within 24 hours of injury, and weekly thereafter for up to three doses during the intensive care unit admission. The primary outcome will be the combined proportion of unfavourable neurological outcomes at six months: severe disability or death. Secondary outcomes will include the rate of proximal deep venous thrombosis detected by compression Doppler ultrasound, six-month mortality, the proportion of patients with composite vascular events (deep venous thrombosis, pulmonary embolism, myocardial infarction, cardiac arrest and cerebrovascular events) at six months and quality of life with health economic evaluations. When completed, the trial aims to provide evidence on the efficacy and safety of erythropoietin in traumatic brain injury patients, and to provide clear guidance for clinicians in their management of this devastating condition. Australian New Zealand Clinical Trials registry: ACTRN12609000827235 (registered on 22 September 2009). Clinicaltrials.gov: NCT00987454 (registered on 29 September 2009). European Drug Regulatory Authorities Clinical Trials: 2011-005235-22 (registered on 18 January 2012).

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 <1%
Unknown 118 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 13%
Student > Ph. D. Student 14 12%
Student > Master 14 12%
Student > Bachelor 12 10%
Student > Doctoral Student 9 8%
Other 26 22%
Unknown 28 24%
Readers by discipline Count As %
Medicine and Dentistry 43 36%
Nursing and Health Professions 11 9%
Social Sciences 7 6%
Agricultural and Biological Sciences 4 3%
Psychology 4 3%
Other 15 13%
Unknown 35 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2016.
All research outputs
#9,147,521
of 15,937,237 outputs
Outputs from Trials
#2,498
of 4,212 outputs
Outputs of similar age
#100,477
of 221,361 outputs
Outputs of similar age from Trials
#1
of 1 outputs
Altmetric has tracked 15,937,237 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,212 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 221,361 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them